search
Back to results

Protective Ventilatory Strategy in Severe Acute Brain Injury (PROLABI)

Primary Purpose

Injuries, Acute Brain

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Conventional Ventilatory Strategy
Protective Ventilatory Strategy
Sponsored by
University of Turin, Italy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Injuries, Acute Brain focused on measuring Acute Respiratory Distress Syndrome, Acute Brain Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with severe acute brain injury (traumatic brain injury, subarachnoid haemorrhage, intra-cerebral haemorrhage, and ischemic stroke)
  • Patients with not obey commands and do not open eyes on GCS (Glasgow Coma Scale)
  • Less than 24 hours of mechanical ventilation (expected >72 hours)

Exclusion Criteria:

  • Age < 18 years
  • Diagnosis of ARDS before randomization.
  • Patients unlikely to survive for the next 24 hours in the opinion of ICU consultant.
  • Pregnancy
  • Post-anoxic coma
  • Metabolic or toxic encephalopathy
  • Lack of Informed Consent.

Sites / Locations

  • University of Turin - Department of Anesthesia and Intensive care Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Conventional Ventilatory Strategy

Protective Ventilatory Strategy

Arm Description

Conventional Ventilatory Strategy

Protective ventilatory strategy

Outcomes

Primary Outcome Measures

Proportion of event free survival
Combined end point of "event free survival" defined as survival without ventilator dependency or ARDS* diagnosis *ARDS will be defined according to Berlin definition criteria. If chest x-ray is not immediately available, ARDS diagnosis will be suspected and confirmed later on. Interpretation of bilateral infiltrates on chest x-ray and of heart failure vs. fluid overload was variable and in a large observational study (LUNGSAFE, JAMA. 2016 Feb 23;315:788-800) hypoxemic patients with new infiltrates were described as a well-defined group with outcome, risk factors, comorbidities and clinical management similar to ARDS. Therefore, in March 2016 the study protocol replaced "ARDS" with "acute hypoxemic respiratory failure" as one of the components of the composite primary endpoint. Acute hypoxemic respiratory failure was defined as PaO2/FiO2 ratio < 300, with presence of infiltrates on chest x-ray, independently of lung opacities distribution and characteristics.

Secondary Outcome Measures

Number of ventilator free days at 28 days
number of ICU free days at day 28 after randomization
Incidence of ventilator associated pneumonia (VAP)
Cumulative SOFA free score from the randomization to day 28
Concentrations of plasma inflammatory cytokines
Modify Oxford Handicap Scale at ICU discharge
Glasgow Outcome Scale extended (GOSe) at 6 months
Mortality at day 28 after randomization
LOS in ICU
length of stay in intensive care unit
Hospital length of stay (HLOS)
length of stay in hospital

Full Information

First Posted
September 12, 2012
Last Updated
April 22, 2021
Sponsor
University of Turin, Italy
search

1. Study Identification

Unique Protocol Identification Number
NCT01690819
Brief Title
Protective Ventilatory Strategy in Severe Acute Brain Injury
Acronym
PROLABI
Official Title
Protective Ventilatory Strategy in Severe Acute Brain Injury: Randomized Multi-center Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 2013 (undefined)
Primary Completion Date
December 2018 (Actual)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Turin, Italy

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute respiratory distress syndrome (ARDS) occurs in almost 20% of patients with severe acute brain injury and is associated with increased morbidity and mortality. A massive increase in sympathetic activity and an increased production of proinflammatory cytokines released into the systemic circulation are the most important recognized mechanisms. Altered blood brain barrier after injury causes spillover of inflammatory mediators from the brain into the systemic circulation leading to peripheral organs damage. The adrenergic surge induces an increase in vascular hydrostatic pressure and lung capillary permeability, causing an alteration of alveolar capillary barrier with fluid accumulation, resulting in ARDS. The main goal of mechanical ventilation after acute brain injury are the maintenance of optimal oxygenation, and a tight control of carbon dioxide tension, although ventilatory settings to be used to obtain these targets, while avoiding secondary insults to the brain, are not clearly identified. Protective ventilatory strategy has been positively evaluated first in patients with ARDS, and then in those undergoing cardiopulmonary bypass or lung resection surgery, or in brain death organ donors, but data on the effect of protective mechanical ventilation on patients with acute brain injury are still lacking even if this is a population with recognized risk factors for ARDS. Therefore, the primary aim of this multi-center, prospective, randomized, controlled trial is to investigate whether a protective ventilatory strategy, in the early phase after severe acute brain injury, is associated with a lower incidence of ARDS, avoiding any further damage to the brain. Secondary aim is to evaluate if a protective ventilatory strategy is associated with reduced duration of mechanical ventilation, incidence of organ failure, intensive care unit length of stay, and lower concentrations of plasma inflammatory cytokines, without adversely affect in neurological outcome.
Detailed Description
BACKGROUND Acute respiratory distress syndrome (ARDS) is described as the most common non-neurologic organ dysfunction occurring in the early phase after severe acute brain injury, with a reported incidence of 10-15% and increased morbidity and mortality. A significant role has been recently proposed for neuro-inflammation in the genesis of ARDS following acute brain injury. The neuro-inflammatory response represents initially a coordinated effort to protect the brain after injury, but may then become altered and be responsible for the activation of the secondary injury cascade leading to single or multiple organ dysfunction. This preclinical event may increase the susceptibility of lungs to the stress of injurious mechanical ventilation. The main targets of ventilatory management of acute brain injury patients are maintenance of an optimal oxygenation, and a tight arterial carbon dioxide control. Actual Guidelines for the management of severe traumatic brain injury, in particular, state that hypoxia (PaO2 <60 mmHg or SaO2 < 90%) should be avoided and PaCO2 level tightly controlled with a target of 35-38 mmHg. However, no published recommendation exists on which ventilator setting, in terms of tidal volume, respiratory rate, and positive end-expiratory pressure (PEEP) levels, should be used to obtain these respiratory targets. In previous studies on patients with ARDS, mechanical ventilation with a low tidal volume and moderate PEEP levels resulted in decreased mortality and increased number of ventilatory free days, and it now represents the standard of care for these patients. Patients with acute brain injury represent a category at risk to develop ARDS both because of the adrenergic cascade and the inflammatory reaction, and because of the ventilatory strategy implemented to optimize gas exchange. Nevertheless, no clinical trial has been performed to evaluate the effect of protective ventilatory strategies upon severe acute brain injury patients. AIMS The aim of this study is to investigate whether the application of a protective ventilatory strategy, defined as low tidal volume and moderate levels of PEEP, improves the combined end point of "event free survival" defined as survival without ventilator dependency or ARDS diagnosis, without adversely affecting neurological outcome. Secondary aim of this study is to evaluate if protective ventilatory strategy may increase number of ventilator and organ failure free days, reduce intensive care unit (ICU) length of stay, reduce the incidence of ventilator associated pneumonia (VAP), reduce concentrations of plasma inflammatory cytokines (IL-6, TNF-alpha, TNF-RI/II, IL-8, IL-1ra, IL-1beta), without adversely affecting neurological outcome as measured by the Modified Oxford Handicap scale at intensive care unit discharge and the Glasgow Outcome Scale-extended (GOSe) at 6 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Injuries, Acute Brain
Keywords
Acute Respiratory Distress Syndrome, Acute Brain Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
524 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conventional Ventilatory Strategy
Arm Type
Active Comparator
Arm Description
Conventional Ventilatory Strategy
Arm Title
Protective Ventilatory Strategy
Arm Type
Experimental
Arm Description
Protective ventilatory strategy
Intervention Type
Procedure
Intervention Name(s)
Conventional Ventilatory Strategy
Intervention Description
The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
Intervention Type
Procedure
Intervention Name(s)
Protective Ventilatory Strategy
Intervention Description
The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
Primary Outcome Measure Information:
Title
Proportion of event free survival
Description
Combined end point of "event free survival" defined as survival without ventilator dependency or ARDS* diagnosis *ARDS will be defined according to Berlin definition criteria. If chest x-ray is not immediately available, ARDS diagnosis will be suspected and confirmed later on. Interpretation of bilateral infiltrates on chest x-ray and of heart failure vs. fluid overload was variable and in a large observational study (LUNGSAFE, JAMA. 2016 Feb 23;315:788-800) hypoxemic patients with new infiltrates were described as a well-defined group with outcome, risk factors, comorbidities and clinical management similar to ARDS. Therefore, in March 2016 the study protocol replaced "ARDS" with "acute hypoxemic respiratory failure" as one of the components of the composite primary endpoint. Acute hypoxemic respiratory failure was defined as PaO2/FiO2 ratio < 300, with presence of infiltrates on chest x-ray, independently of lung opacities distribution and characteristics.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Number of ventilator free days at 28 days
Time Frame
28 days
Title
number of ICU free days at day 28 after randomization
Time Frame
participants will be followed for the duration of ICU stay, an expected average of 3 weeks
Title
Incidence of ventilator associated pneumonia (VAP)
Time Frame
28 days
Title
Cumulative SOFA free score from the randomization to day 28
Time Frame
28 days
Title
Concentrations of plasma inflammatory cytokines
Time Frame
7 days
Title
Modify Oxford Handicap Scale at ICU discharge
Time Frame
participants will be followed for the duration of ICU stay, an expected average of 3 weeks
Title
Glasgow Outcome Scale extended (GOSe) at 6 months
Time Frame
at 6 months
Title
Mortality at day 28 after randomization
Time Frame
28 days
Title
LOS in ICU
Description
length of stay in intensive care unit
Time Frame
20 days (average time)
Title
Hospital length of stay (HLOS)
Description
length of stay in hospital
Time Frame
30 days (average time)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with severe acute brain injury (traumatic brain injury, subarachnoid haemorrhage, intra-cerebral haemorrhage, and ischemic stroke) Patients with not obey commands and do not open eyes on GCS (Glasgow Coma Scale) Less than 24 hours of mechanical ventilation (expected >72 hours) Exclusion Criteria: Age < 18 years Diagnosis of ARDS before randomization. Patients unlikely to survive for the next 24 hours in the opinion of ICU consultant. Pregnancy Post-anoxic coma Metabolic or toxic encephalopathy Lack of Informed Consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luciana Mascia, MD, PhD
Organizational Affiliation
University of Turin, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Turin - Department of Anesthesia and Intensive care Medicine
City
Turin
ZIP/Postal Code
10126
Country
Italy

12. IPD Sharing Statement

Links:
URL
http://prolabi.ddmc.unito.it
Description
Related Info

Learn more about this trial

Protective Ventilatory Strategy in Severe Acute Brain Injury

We'll reach out to this number within 24 hrs